Nevertheless, the influence of systemic therapy on recurrence patterns may change now that adjuvant chemo/immunotherapy in programmed death-ligand 1 (PD-L1)–positive NSCLC,23 adjuvant osimertinib in EGFRmut NSCLC,24 and neoadjuvant chemo/immunotherapy25 have received Food and Drug Administration approval based on their DFS benefits. Here, CD274 is linked to non-small cell lung carcinoma.